Zerumbone Alleviates Neuropathic Pain through the Involvement of L-Arginine-Nitric Oxide-cGMP-K+ ATP Channel Pathways in Chronic Constriction Injury in Mice Model

Nurul Atiqah Zulazmi, Banulata Gopalsamy, Jasmine Chia Siew Min, Ahmad Akira Omar Farouk, Mohd Roslan Sulaiman, B. Hemabarathy Bharatham, Enoch Kumar Perimal

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The present study investigates the involvement of the L-Arginine-Nitric Oxide-cGMP-K+ ATP pathways responsible for the action of anti-Allodynic and antihyperalgesic activities of zerumbone in chronic constriction injury (CCI) induced neuropathic pain in mice. The role of L-Arginine-NO-cGMP-K+ was assessed by the von Frey and the Randall-Selitto tests. Both allodynia and hyperalgesia assessments were carried out on the 14th day post CCI, 30 min after treatments were given for each respective pathway. Anti-Allodynic and antihyperalgesic effects of zerumbone (10 mg/kg, i.p) were significantly reversed by the pre-Treatment of L-Arginine (10 mg/kg), 1H [1,2,4]Oxadiazole[4,3a]quinoxalin-1-one (ODQ), a soluble guanosyl cyclase blocker (2 mg/kg i.p.) and glibenclamide (ATP-sensitive potassium channel blocker) (10 mg/kg i.p.) (p < 0.05). Taken together, these results indicate that systemic administration of zerumbone produces significant anti-Allodynic and antihyperalgesic activities in neuropathic pain in mice possibly due to involvement of the L-Arginine-NO-cGMP-PKG-K+ ATP channel pathways in CCI model.

Original languageEnglish
Article number555
JournalMolecules
Volume22
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint

pain
adenosine triphosphate
Neuralgia
nitric oxide
Constriction
mice
Arginine
constrictions
Nitric Oxide
Adenosine Triphosphate
Hyperalgesia
Wounds and Injuries
quinoxalines
Potassium Channel Blockers
Oxadiazoles
Quinoxalines
pretreatment
KATP Channels
Glyburide
zerumbone

Keywords

  • Chronic constriction injury (CCI)
  • Neuropathic pain
  • Nitric oxide
  • NO-cGMP pathway
  • Zerumbone

ASJC Scopus subject areas

  • Medicine(all)
  • Organic Chemistry

Cite this

Zerumbone Alleviates Neuropathic Pain through the Involvement of L-Arginine-Nitric Oxide-cGMP-K+ ATP Channel Pathways in Chronic Constriction Injury in Mice Model. / Zulazmi, Nurul Atiqah; Gopalsamy, Banulata; Min, Jasmine Chia Siew; Farouk, Ahmad Akira Omar; Sulaiman, Mohd Roslan; Bharatham, B. Hemabarathy; Perimal, Enoch Kumar.

In: Molecules, Vol. 22, No. 4, 555, 01.04.2017.

Research output: Contribution to journalArticle

Zulazmi, Nurul Atiqah ; Gopalsamy, Banulata ; Min, Jasmine Chia Siew ; Farouk, Ahmad Akira Omar ; Sulaiman, Mohd Roslan ; Bharatham, B. Hemabarathy ; Perimal, Enoch Kumar. / Zerumbone Alleviates Neuropathic Pain through the Involvement of L-Arginine-Nitric Oxide-cGMP-K+ ATP Channel Pathways in Chronic Constriction Injury in Mice Model. In: Molecules. 2017 ; Vol. 22, No. 4.
@article{43cbb8b3c49f431ea9143bec7d95abd6,
title = "Zerumbone Alleviates Neuropathic Pain through the Involvement of L-Arginine-Nitric Oxide-cGMP-K+ ATP Channel Pathways in Chronic Constriction Injury in Mice Model",
abstract = "The present study investigates the involvement of the L-Arginine-Nitric Oxide-cGMP-K+ ATP pathways responsible for the action of anti-Allodynic and antihyperalgesic activities of zerumbone in chronic constriction injury (CCI) induced neuropathic pain in mice. The role of L-Arginine-NO-cGMP-K+ was assessed by the von Frey and the Randall-Selitto tests. Both allodynia and hyperalgesia assessments were carried out on the 14th day post CCI, 30 min after treatments were given for each respective pathway. Anti-Allodynic and antihyperalgesic effects of zerumbone (10 mg/kg, i.p) were significantly reversed by the pre-Treatment of L-Arginine (10 mg/kg), 1H [1,2,4]Oxadiazole[4,3a]quinoxalin-1-one (ODQ), a soluble guanosyl cyclase blocker (2 mg/kg i.p.) and glibenclamide (ATP-sensitive potassium channel blocker) (10 mg/kg i.p.) (p < 0.05). Taken together, these results indicate that systemic administration of zerumbone produces significant anti-Allodynic and antihyperalgesic activities in neuropathic pain in mice possibly due to involvement of the L-Arginine-NO-cGMP-PKG-K+ ATP channel pathways in CCI model.",
keywords = "Chronic constriction injury (CCI), Neuropathic pain, Nitric oxide, NO-cGMP pathway, Zerumbone",
author = "Zulazmi, {Nurul Atiqah} and Banulata Gopalsamy and Min, {Jasmine Chia Siew} and Farouk, {Ahmad Akira Omar} and Sulaiman, {Mohd Roslan} and Bharatham, {B. Hemabarathy} and Perimal, {Enoch Kumar}",
year = "2017",
month = "4",
day = "1",
doi = "10.3390/molecules22040555",
language = "English",
volume = "22",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

TY - JOUR

T1 - Zerumbone Alleviates Neuropathic Pain through the Involvement of L-Arginine-Nitric Oxide-cGMP-K+ ATP Channel Pathways in Chronic Constriction Injury in Mice Model

AU - Zulazmi, Nurul Atiqah

AU - Gopalsamy, Banulata

AU - Min, Jasmine Chia Siew

AU - Farouk, Ahmad Akira Omar

AU - Sulaiman, Mohd Roslan

AU - Bharatham, B. Hemabarathy

AU - Perimal, Enoch Kumar

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The present study investigates the involvement of the L-Arginine-Nitric Oxide-cGMP-K+ ATP pathways responsible for the action of anti-Allodynic and antihyperalgesic activities of zerumbone in chronic constriction injury (CCI) induced neuropathic pain in mice. The role of L-Arginine-NO-cGMP-K+ was assessed by the von Frey and the Randall-Selitto tests. Both allodynia and hyperalgesia assessments were carried out on the 14th day post CCI, 30 min after treatments were given for each respective pathway. Anti-Allodynic and antihyperalgesic effects of zerumbone (10 mg/kg, i.p) were significantly reversed by the pre-Treatment of L-Arginine (10 mg/kg), 1H [1,2,4]Oxadiazole[4,3a]quinoxalin-1-one (ODQ), a soluble guanosyl cyclase blocker (2 mg/kg i.p.) and glibenclamide (ATP-sensitive potassium channel blocker) (10 mg/kg i.p.) (p < 0.05). Taken together, these results indicate that systemic administration of zerumbone produces significant anti-Allodynic and antihyperalgesic activities in neuropathic pain in mice possibly due to involvement of the L-Arginine-NO-cGMP-PKG-K+ ATP channel pathways in CCI model.

AB - The present study investigates the involvement of the L-Arginine-Nitric Oxide-cGMP-K+ ATP pathways responsible for the action of anti-Allodynic and antihyperalgesic activities of zerumbone in chronic constriction injury (CCI) induced neuropathic pain in mice. The role of L-Arginine-NO-cGMP-K+ was assessed by the von Frey and the Randall-Selitto tests. Both allodynia and hyperalgesia assessments were carried out on the 14th day post CCI, 30 min after treatments were given for each respective pathway. Anti-Allodynic and antihyperalgesic effects of zerumbone (10 mg/kg, i.p) were significantly reversed by the pre-Treatment of L-Arginine (10 mg/kg), 1H [1,2,4]Oxadiazole[4,3a]quinoxalin-1-one (ODQ), a soluble guanosyl cyclase blocker (2 mg/kg i.p.) and glibenclamide (ATP-sensitive potassium channel blocker) (10 mg/kg i.p.) (p < 0.05). Taken together, these results indicate that systemic administration of zerumbone produces significant anti-Allodynic and antihyperalgesic activities in neuropathic pain in mice possibly due to involvement of the L-Arginine-NO-cGMP-PKG-K+ ATP channel pathways in CCI model.

KW - Chronic constriction injury (CCI)

KW - Neuropathic pain

KW - Nitric oxide

KW - NO-cGMP pathway

KW - Zerumbone

UR - http://www.scopus.com/inward/record.url?scp=85016973672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016973672&partnerID=8YFLogxK

U2 - 10.3390/molecules22040555

DO - 10.3390/molecules22040555

M3 - Article

C2 - 28358309

AN - SCOPUS:85016973672

VL - 22

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 4

M1 - 555

ER -